theory clinical_104_4
imports Main

begin

typedecl entity
typedecl event

consts
  Inhibitor :: "entity ⇒ bool"
  Irreversible :: "entity ⇒ bool"
  TargetedTo :: "entity ⇒ entity ⇒ bool"
  HER2KinaseDomain :: "entity ⇒ bool"
  Overcome :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  TrastuzumabResistance :: "entity ⇒ bool"
  InducedBy :: "entity ⇒ entity ⇒ bool"
  HER2V777L :: "entity ⇒ bool"
  Trastuzumab :: "entity ⇒ bool"
  ExtracellularKinaseDomain :: "entity ⇒ bool"
  Cause :: "event ⇒ bool"
  ResistanceTo :: "event ⇒ entity ⇒ bool"
  Bind :: "event ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  IntracellularKinaseDomain :: "entity ⇒ bool"
  Mutation :: "entity ⇒ bool"
  Targeting :: "entity ⇒ bool"
  HERV777LMutation :: "entity ⇒ bool"
  TyrosineKinaseInhibitor :: "entity ⇒ bool"
  Resistance :: "entity ⇒ bool"
  CausedBy :: "entity ⇒ entity ⇒ bool"
  Contribute :: "event ⇒ bool"
  OvercomingTreatmentResistance :: "event ⇒ bool"
  Implies :: "event ⇒ bool"
  HER2ActivatingMutation :: "entity ⇒ bool"  (* Added missing consts definition *)

(* Explanation 1: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation. *)
axiomatization where
  explanation_1: "∃x y z w e. Inhibitor x ∧ Irreversible x ∧ TargetedTo x y ∧ HER2KinaseDomain y ∧ Overcome e ∧ Agent e x ∧ TrastuzumabResistance z ∧ InducedBy z w ∧ HER2ActivatingMutation w"

(* Explanation 2: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain. *)
axiomatization where
  explanation_2: "∃x y z e1 e2. HER2V777L x ∧ Trastuzumab y ∧ ExtracellularKinaseDomain z ∧ Cause e1 ∧ Agent e1 x ∧ ResistanceTo e1 y ∧ Bind e2 ∧ Agent e2 y ∧ Patient e2 z ∧ IntracellularKinaseDomain z ∧ Mutation x"

(* Explanation 3: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can directly overcome the resistance caused by the HER2 V777L mutation, and this action directly contributes to overcoming treatment resistance. *)
axiomatization where
  explanation_3: "∃x y z e1 e2. Targeting x ∧ HERV777LMutation y ∧ TyrosineKinaseInhibitor x ∧ Irreversible x ∧ Overcome e1 ∧ Agent e1 x ∧ Resistance z ∧ CausedBy z y ∧ Contribute e2 ∧ Agent e2 x ∧ OvercomingTreatmentResistance e2"

(* Explanation 4: Overcoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance. *)
axiomatization where
  explanation_4: "∃x y e1. Resistance x ∧ HER2V777LMutation y ∧ CausedBy x y ∧ Overcome e1 ∧ Agent e1 x ∧ OvercomingTreatmentResistance e1"

theorem hypothesis:
  assumes asm: "HERV777LMutation y ∧ TreatmentResistance y"
  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)
  shows "∃x y e. Targeting x ∧ HERV777LMutation y ∧ TyrosineKinaseInhibitor x ∧ Irreversible x ∧ Overcome e ∧ Agent e x ∧ Patient e y ∧ TreatmentResistance y"
proof -
  (* From the premise, we have known information about the HER V777L mutation and treatment resistance. *)
  from asm have "HERV777LMutation y ∧ TreatmentResistance y" <ATP>
  (* There is a logical relation Implies(G, I), which states that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor implies overcoming treatment resistance. *)
  (* Explanation 3 provides the necessary conditions for G, which includes targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor. *)
  (* We can use this to infer that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)
  then have "∃x e. Targeting x ∧ HERV777LMutation y ∧ TyrosineKinaseInhibitor x ∧ Irreversible x ∧ Overcome e ∧ Agent e x ∧ OvercomingTreatmentResistance e" <ATP>
  (* Since we have TreatmentResistance y from the premise, we can conclude the hypothesis. *)
  then show ?thesis <ATP>
qed

end
